Trial Profile
Risk of interstitial lung disease in patients with Rheumatoid arthritis receieving Tocilizumab, Rituximab, Abatacept and anti-tumor necrosis factor alpha agents:A retospective,cohort study
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 30 Sep 2016
Price :
$35
*
At a glance
- Drugs Abatacept (Primary) ; Rituximab (Primary) ; Tocilizumab (Primary)
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- 30 Sep 2016 New trial record